Strategic partnerships Atlas Antibodies leverages a strong legacy from the Human Protein Atlas and actively pursues collaborations such as the Lumito imaging integration, presenting a sales opportunity to position combined solutions for tissue analysis and quantitative proteomics.

High value portfolio The company offers extensively validated primary antibodies across IHC, WB, and IF with openly available validation data, enabling you to upsell to research groups prioritizing data reproducibility and reliability in oncology, neuroscience, and cell biology.

Spatial biology edge With MolBoolean and AtlasPlex platforms, Atlas Antibodies targets advanced spatial proteomics, creating cross-sell potential to labs expanding in situ analysis and high-throughput multiplex workflows.

Leadership & continuity Recent executive changes with Ingela Hofverberg as CEO and a track record in transformation and quality suggest stability and a clear strategic direction, which can reassure customers and channel partners during negotiations.

Acquisitions & expansion Past acquisitions (HistoCyte Laboratories, Evitria) and expansion into monoclonal PrecisA antibodies indicate a growth trajectory and an openness to integrate complementary capabilities, opening up opportunities for bundled solutions and expanded service offerings.